GLP-1 analogues and obesity: we are taking steps to make their use safer in France

News Healthcare & Pharma Guidance

Date: 13th Nov, 2024 Source: French National Agency for the Safety of Medicines and Health Products (ANSM) Country: France Original Source

Brief

On "13/11/2024", the French National Agency for the Safety of Medicines and Health Products (ANSM) issued an update regarding GLP-1 analogues and obesity: we are taking steps to make their use safer in France. The update restricts conditions of prescription and delivery for GLP-1 analogues, requiring a specialist doctor or nutritionist for initial prescriptions and any subsequent renewals.

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

GLP-1 analogues and obesity: we are taking steps to make their use safer in France

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

GLP-1 analogues and obesity: we are taking steps to make their use safer in France

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.